The best peptides for weight-loss research

This guide reflects our reading of the clinical literature published in 2026. We rank the compounds below by receptor coverage and by the results recorded in the studies, not by marketing claims, and we flag where the evidence is still preliminary.

Weight-loss peptides: the essentials

• Retatrutide is, in 2026, the only triple agonist on the research market and acts on the GLP-1, GIP and glucagon receptors at the same time; phase 2 data recorded a mean weight loss of 24.2% at 48 weeks.
• Tirzepatide (a dual GLP-1/GIP agonist) and semaglutide (a single GLP-1 agonist) have completed phase 3 obesity trials and are authorised as medicines under the names Mounjaro and Wegovy respectively.
• CagriSema combines cagrilintide (an amylin analogue) with semaglutide; interim data from the phase 3 REDEFINE 1 trial (2024) recorded a mean weight reduction of 22.7%, with the full peer-reviewed results published in NEJM in 2025.
• Tesamorelin (a GHRH analogue) acts on visceral fat through growth hormone release, not through appetite suppression; the evidence remains centred on HIV-associated lipodystrophy.
• All five compounds are supplied as research peptides solely for laboratory use and are not medicines authorised for human use.

---

The best peptides for weight loss in 2026, ranked by receptor coverage and published efficacy, are:

• Retatrutide, a triple GLP-1/GIP/glucagon agonist; up to 24.2% mean weight loss at 48 weeks in the phase 2 obesity trial published in NEJM in 2023, and 25.0% mean weight loss at 80 weeks with 12 mg (against 3.9% with placebo) in the phase 3 TRIUMPH-1 trial published in NEJM in 2026 [1][8][17].
• Tirzepatide, a dual GLP-1/GIP agonist; authorised as a prescription-only medicine under the name Mounjaro [11].
• Semaglutide, a single GLP-1 agonist; authorised as a prescription-only medicine under the name Wegovy [6].
• CagriSema, a fixed-dose combination of cagrilintide and semaglutide; interim data from the phase 3 REDEFINE 1 trial were reported in 2024 and the full peer-reviewed results were published in NEJM in 2025 [10].
• Tesamorelin, a GHRH analogue for the reduction of visceral adipose tissue, documented above all in HIV-associated lipodystrophy [9].

This guide explains how these research compounds differ in receptor coverage, study maturity and research utility, how to choose the right peptide for your protocol, and what the regulatory difference is between a research compound and an authorised medicine. To define the scope: this is a ranked comparison of the GLP-1/GIP/glucagon research peptides handled in in vitro and analytical work. It is not a guide to prescription weight-loss medicines such as Wegovy or Mounjaro, which belong to their own regulatory category and are covered further down.

Top picks: best research peptides for weight loss (2026)

Ranked by receptor coverage and by the maturity of the published studies, these are the research compounds we rate most highly in 2026 for weight-loss research with GLP-1/GIP/glucagon. Each pick is a research peptide from the Body Pharm catalogue, supplied solely for in vitro and laboratory use.

• Best overall / most complete mechanism: Retatrutide 64 mg. The only triple GLP-1/GIP/glucagon agonist in the catalogue; the additional glucagon arm is the mechanistic basis for the 24.2% mean weight loss at 48 weeks in the phase 2 obesity trial published in NEJM in 2023 [1]. The 64 mg pen suits extended protocols that escalate to the high-dose arms of phase 2.
• Best value / entry point: Retatrutide 32 mg. The same triple agonist with a smaller reservoir, ideal for initial tolerability screens that reproduce the weekly 1 to 4 mg titration schedule before starting a full protocol.
• Best dual-incretin comparator: Tirzepatide 60 mg. A dual GLP-1/GIP agonist with completed phase 3 evidence (SURMOUNT); the reference compound for isolating the additional contribution of the GIP arm over a single agonist.

Full details of receptor coverage and evidence for each pick follow below.

What are research peptides for weight loss?

Research peptides for weight loss are synthetic incretin mimetics and growth hormone-releasing hormone analogues supplied for in vitro and preclinical work, not for human use. They replicate endogenous hormones that regulate appetite, gastric emptying, insulin secretion and lipolysis, and they are sold solely as laboratory reagents, outside the medicinal product authorisation route.

The five compounds compared in this guide act on four distinct receptor systems:

• GLP-1 receptor: slows gastric emptying and signals satiety through the arcuate nucleus of the hypothalamus; the target of semaglutide, tirzepatide, retatrutide and the semaglutide component of CagriSema.
• GIP receptor: modulates adipocyte lipid metabolism and reinforces the GLP-1-driven insulin response; a target shared by tirzepatide and retatrutide.
• Glucagon receptor: raises resting energy expenditure and hepatic lipid oxidation; among the compounds considered, only retatrutide adds it.
• Amylin receptor: slows gastric emptying and reduces postprandial glucagon; the target of the cagrilintide half of CagriSema.
• GHRH receptor: stimulates pulsatile growth hormone release and so indirectly reduces visceral adipose tissue; the mechanism of tesamorelin [9].

GLP-1 was first characterised in the 1980s as a cleavage product of proglucagon, with a native half-life of about two minutes. Modern analogues such as semaglutide extend that half-life to around seven days by means of fatty-acid side chains that bind albumin, which makes weekly dosing possible [6].

Regulatory position

Research peptides occupy a narrow legal position. A peptide that is marketed, labelled or presented to treat disease or to influence physiological functions is regarded as a medicinal product requiring authorisation, regardless of whether it carries a "research use only" label [3]. The authorised medicines for weight reduction are Wegovy (semaglutide), Mounjaro (tirzepatide) and Saxenda (liraglutide), all prescription-only [6][11][12]. As far as we know, in 2026 neither retatrutide nor CagriSema nor tesamorelin holds an authorisation for the obesity indication [14].

For a deeper mechanistic breakdown of the three main incretin compounds, see our comparison Retatrutide vs. semaglutide vs. tirzepatide; for titration details, the protocol page How to dose retatrutide.

How we assessed these peptides

Our 2026 assessment uses a four-axis framework developed by the Body Pharm research team that weighs research utility without claiming anything about clinical efficacy. We scored each peptide on receptor coverage, level of evidence, titration complexity and format flexibility, then ranked them by total score.

Receptor coverage (1–3): a single-receptor agonist (semaglutide, tesamorelin) receives 1 point; dual agonists (tirzepatide, CagriSema) receive 2 points; the triple agonist retatrutide receives 3 points. Broader coverage correlates with a broader metabolic mechanism, not necessarily with better outcomes.

Level of evidence: anchored to the highest completed study phase in 2026. Semaglutide and tirzepatide have completed phase 3 obesity data; retatrutide and CagriSema have had published phase 3 results since 2025-2026 (TRIUMPH-1 and REDEFINE 1) [10][17]; tesamorelin's phase 3 evidence remains centred on HIV-associated lipodystrophy, with no large non-HIV obesity trials between 2024 and 2026 [9].

Titration complexity: scored on the number of escalation steps, the length of the intervals and whether sub-milligram precision is required. Retatrutide's phase 2 schedule, from 1 to 12 mg [1], is more demanding than semaglutide's four-step monthly escalation.

Format and dose flexibility: a pre-filled multi-dose pen dials the dose directly in milligrams on the dose dial and covers the whole titration schedule from a single cartridge, with no prior preparation. This axis favours the compounds Body Pharm supplies in pen format.

The ranking reflects suitability for controlled research workflows in 2026. For the direct incretin comparison, see Retatrutide vs. semaglutide vs. tirzepatide; for protocol details, the page How to dose retatrutide.

Receptor coverage at a glance: 2026 comparison table

Retatrutide is, in 2026, the only triple agonist on the research market and acts on the GLP-1, GIP and glucagon receptors at once [1]. The table below compares the five compounds by mechanism, total peptide per pen, 2026 Body Pharm list price and level of evidence.

The essentials

Retatrutide's phase 2 data published in NEJM recorded up to a 24.2% mean reduction in body weight at 48 weeks with the 12 mg dose [1]. CagriSema is structurally distinct because it combines cagrilintide (an amylin analogue) with semaglutide and so adds a satiety pathway that pure incretin agonists do not address [4]. Tesamorelin sits entirely outside the incretin class, acts through growth hormone release and currently lacks large non-HIV obesity trials between 2024 and 2026 [9].

For a deeper incretin comparison, see Retatrutide vs. semaglutide vs. tirzepatide. If you choose retatrutide, review the titration schedule in How to dose retatrutide before dialling the first dose.

Retatrutide: triple agonist for fat-loss research

Retatrutide (LY3437943) activates the GIP, GLP-1 and glucagon receptors simultaneously, and in 2026 it is the only compound on the research market that does so [1]. The glucagon receptor arm is the distinguishing mechanistic feature: glucagon activation raises resting energy expenditure and drives hepatic lipid oxidation, two pathways that tirzepatide and semaglutide do not address [1].

Why triple agonism matters in fat-loss research

GIP and GLP-1 activation suppresses appetite and improves glucose utilisation, but glucagon activation adds a thermogenic component. In the phase 2 trial by Jastreboff et al. published in NEJM (June 2023), the dose-dependent reduction in body weight reached a mean of 24.2% at 48 weeks with 12 mg weekly in adults with obesity [1]. Eli Lilly's phase 3 programme is still ongoing in 2026, so any comparison with tirzepatide and semaglutide rests on phase 2 evidence and not on head-to-head phase 3 results [8].

Some researchers point out that retatrutide still has no long-term cardiovascular outcome data; even so, with the phase 3 TRIUMPH-1 results published in 2026 [17] and the phase 2 publication in NEJM, it has a solid mechanistic and efficacy basis for controlled research protocols.

32 mg versus 64 mg: which pen researchers choose

The two available pen sizes reflect different titration windows, not different molecules. The number in the name is the total amount of peptide the pen contains; the dose is dialled the same way on both.

Retatrutide 32 mg suits early-phase protocols that reproduce the NEJM weekly 1 to 4 mg titration schedule.

Retatrutide 64 mg is chosen for extended protocols that escalate to 8 mg or 12 mg weekly, equivalent to the high-dose arms of Jastreboff et al. 2023 [1]. The larger pen does not change the dose: it simply lasts longer.

Body Pharm supplies both sizes as pre-filled multi-dose pens with a 3 ml cartridge. The dose dial reads directly in milligrams, so there is no reconstitution and no calculation beforehand. It is worth requesting the batch-specific certificate of analysis (CoA) (HPLC purity, mass-spectrometry confirmation) for every batch used in longitudinal studies, because it provides the traceability needed to attribute observed results to a specific production batch.

For the full titration schedule (1 mg → 12 mg over 20 weeks, analogous to the phase 2 protocol), see How to dose retatrutide. For mechanistic and efficacy comparisons within the incretin class, see Retatrutide vs. semaglutide vs. tirzepatide.

Pricing and supply in 2026

Current prices for Retatrutide 32 mg (€249) and 64 mg (€379) are published on their respective product pages and are updated according to batch availability; check the current product page before ordering. Every pen is delivered with a batch number traceable to the certificate of analysis, the minimum standard for reproducible research work.

For research use only. Retatrutide is not an authorised medicine and is not authorised for therapeutic use in humans [14]. It must not be administered to humans or animals and is supplied solely for in vitro and laboratory research under appropriate institutional supervision.

Tirzepatide: dual GIP/GLP-1 agonist as a research peptide

Tirzepatide is a dual co-agonist of the GIP and GLP-1 receptors which, in SURMOUNT-1 (Jastreboff et al., NEJM, 2022), achieved a mean body-weight reduction of 22.5% at 72 weeks in the 15 mg arm, against 2.4% with placebo [2]. The GIP arm is what sets it apart from semaglutide: GIP co-agonism reinforces glucose-dependent insulin secretion and, in preclinical and early clinical models, appears to attenuate the nausea signal that single GLP-1 agonists generate at the higher titration steps.

Mechanism: why dual agonism matters

GLP-1 receptor activation drives satiety, delayed gastric emptying and glucose-dependent insulin release. GIP receptor activation adds a second insulinotropic stimulus and modulates adipocyte lipid metabolism. That combined receptor coverage is the reason tirzepatide outperforms semaglutide on weight endpoints in head-to-head obesity trials, and also the reason it sits one step below retatrutide, which adds a glucagon arm to raise energy expenditure. For the full breakdown of all three, see Retatrutide vs. semaglutide vs. tirzepatide.

Research dose titration

The SURMOUNT-1 protocol escalated in 4-week steps from 2.5 mg weekly to maintenance doses of 5 mg, 10 mg or 15 mg. Most research replications use the same schedule: 2.5 mg in weeks 1–4, 5 mg in weeks 5–8 and then dose-finding up to 10 mg or 15 mg according to tolerability endpoints.

Presentation and price in 2026

The Tirzepatide 60 mg pen is the only tirzepatide presentation in the Spanish catalogue. Its 60 mg total covers the full schedule, from the 2.5 mg weekly start through to extended maintenance at 10 mg or 15 mg weekly, without reordering mid-study.

Body Pharm offers Tirzepatide 60 mg as a pre-filled multi-dose pen with a 3 ml cartridge and a dose dial that reads in milligrams, with an HPLC and mass-spectrometry certificate of analysis for every batch; the 2026 list price is €199. Shipping to Spain.

Regulatory context

Tirzepatide is authorised as a prescription-only medicine under the name Mounjaro, and in the United States as Zepbound for obesity (FDA, November 2023). The authorised medicine Mounjaro is clearly separated, both in regulatory terms and in the supply chain, from research-grade tirzepatide powder, which is sold solely for in vitro and non-human laboratory use and is not intended for human use.

For the full titration tables, see How to dose tirzepatide.

CagriSema: combined amylin + GLP-1 peptide

CagriSema is a fixed-dose combination of cagrilintide (a long-acting amylin analogue [7]) and semaglutide (a GLP-1 receptor agonist), and is therefore the only amylin/GLP-1 peptide with two signalling pathways in this comparison. Amylin and GLP-1 act on distinct but complementary receptors, so the combination produces additive effects on satiety, gastric emptying and glucagon suppression, rather than the single-axis effect of semaglutide alone.

Why amylin matters alongside GLP-1

Amylin is co-secreted with insulin from the pancreatic beta cells, slows gastric emptying, suppresses postprandial glucagon and acts on neurons of the area postrema in the hindbrain to reinforce satiety. GLP-1 agonism contributes central appetite suppression and glucose-dependent insulin release. Combining both pathways is the mechanistic justification researchers cite when they prefer CagriSema to a pure GLP-1 agonist and the endpoint of interest is maximum appetite reduction with a lower dose of semaglutide.

REDEFINE 1: efficacy signal

Novo Nordisk's phase 3 REDEFINE 1 trial, whose first results were reported in 2024, recorded around a 22.7% mean weight reduction at 68 weeks with CagriSema 2.4 mg/2.4 mg, against 16.1% with semaglutide 2.4 mg alone (trial-product estimand; 20.4% against 3.0% with placebo under the treatment-policy estimand) [10]. The full peer-reviewed publication appeared in NEJM in 2025 (Garvey et al.), so the 22.7% figure no longer depends on the company-reported analyses [10].

Research dose titration

Replication protocols follow the trial schedule: 0.25 mg/0.25 mg weekly for 4 weeks, then at 4-week intervals 0.5/0.5, 1.0/1.0 and 1.7/1.7 up to 2.4/2.4 mg weekly. You will find the full titration tables in How to dose CagriSema.

Availability

CagriSema is dealt with exclusively in the context of in vitro and non-human laboratory research; it is not intended for human use. Body Pharm does not currently offer CagriSema in its catalogue.

For the broader incretin comparison, see Retatrutide vs. semaglutide vs. tirzepatide.

Semaglutide as a research peptide: the GLP-1 reference

Semaglutide is the single-receptor GLP-1 agonist against which every dual and triple incretin agonist in this guide is measured. The STEP-1 trial (Wilding et al., NEJM, 2021) recorded a 14.9% mean weight reduction at 68 weeks with semaglutide 2.4 mg weekly [5]; it remains the reference value researchers cite when modelling the additional contribution of GIP, glucagon or amylin co-agonism.

In clinical practice, semaglutide is authorised as a prescription-only medicine under the names Ozempic (type 2 diabetes) and Wegovy (obesity), and is prescribed according to defined BMI and comorbidity criteria [6][13]. These are authorised medicines that must be distinguished, mechanistically and in regulatory terms, from research-grade semaglutide for in vitro work.

Why researchers still choose semaglutide as a single agonist

Single-receptor semaglutide offers cleaner mechanistic isolation than tirzepatide, retatrutide or CagriSema, because it acts only on the GLP-1 receptor. That matters when the research question concerns GLP-1-specific signalling pathways, gastric emptying kinetics, beta-cell insulin secretion or hypothalamic POMC activation, without confounders from the GIP or glucagon receptors. It also provides the comparator arm for in-house dose-response work that measures the newer agonists against the 14.9% STEP-1 reference value.

Single compound versus the CagriSema combination

In CagriSema the semaglutide is co-formulated with cagrilintide at a fixed dose, so combination protocols do not use semaglutide separately. For single-agonist work, semaglutide is used as a single compound; you will find the full titration schedules in How to dose semaglutide.

For the head-to-head breakdown of efficacy and receptor coverage, see Retatrutide vs. semaglutide vs. tirzepatide.

Tesamorelin: GHRH analogue for visceral fat research

Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH) that stimulates endogenous pulsatile GH secretion from the anterior pituitary. It is a radically different mechanism from the GLP-1, GIP, glucagon and amylin receptor agonism covered earlier in this guide. Researchers choose it when the question concerns visceral adipose tissue (VAT) lipolysis mediated by the GH/IGF-1 axis, and not appetite suppression or incretin-driven satiety.

Mechanism and research focus

Tesamorelin binds the GHRH receptor on somatotroph cells and restores the physiological amplitude of GH pulses, rather than producing the flat, supraphysiological exposure of exogenous recombinant growth hormone (rhGH). The subsequent rise in IGF-1 mobilises lipids preferentially from visceral depots rather than subcutaneous fat, which is why the compound remains of interest in VAT-focused body-composition protocols. It does not slow gastric emptying, it does not act on hypothalamic POMC neurons and it does not produce weight loss of the order of retatrutide or tirzepatide. Choose tesamorelin when the endpoint of interest is VAT area on MRI or CT, not total body mass.

Evidence base and limitations in 2026

Tesamorelin (trade name Egrifta) obtained FDA approval in 2010 for HIV-associated lipodystrophy on the basis of Falutz et al. (NEJM, 2007) [9], which remains the most cited VAT-reduction dataset and is now more than fifteen years old. Recent reviews of obesity and body composition from 2024 to 2026 continue to refer to tesamorelin chiefly in the context of HIV-associated lipodystrophy or as an off-label GHRH analogue, rather than citing new large non-HIV VAT trials [9]. Any extrapolation to non-HIV cohorts with metabolic syndrome therefore rests on small pilot work and mechanistic inference, not on 2026 phase 3 evidence.

Availability and price

Body Pharm offers tesamorelin as a 32 mg research pen at a 2026 list price of €139; the full titration protocol is described in How to dose tesamorelin. If you are comparing GH-axis work with incretin-based protocols, the head-to-head receptor breakdown is in Retatrutide vs. semaglutide vs. tirzepatide.

All tesamorelin sold by Body Pharm is supplied solely for in vitro laboratory research and is not a medicine authorised for human use.

GLP-1 peptides for weight loss: the mechanism in detail

GLP-1 receptor agonists produce weight loss through four parallel actions: delayed gastric emptying, hypothalamic appetite suppression, glucose-dependent insulin secretion and glucagon suppression. The GLP-1 receptor is expressed in the hypothalamus, the brainstem, the pancreatic islets and the gastrointestinal tract, which is why a single agonist can modulate satiety, glycaemia and intestinal transit at the same time.

Each of the five compounds in this guide engages that system differently.

Semaglutide binds only the GLP-1 receptor, produces satiety through POMC activation in the arcuate nucleus and slows gastric emptying without any direct involvement of GIP or glucagon.

Tirzepatide adds GIP receptor activity and recruits a complementary incretin axis. GIP co-agonism is thought to improve adipocyte lipid metabolism and insulin sensitivity independently of the GLP-1 signal; the foundational dataset from Finan et al. (Sci Transl Med, 2013) is now more than ten years old [16] and should be treated as mechanistic evidence, not as current efficacy evidence.

Retatrutide adds to GLP-1 and GIP a glucagon arm that raises resting energy expenditure and hepatic lipid oxidation. That is the mechanistic justification for the 24.2% mean weight loss at 48 weeks in the phase 2 obesity cohort [1].

CagriSema combines GLP-1 with amylin: cagrilintide activates the amylin and calcitonin receptors in the area postrema, a satiety pathway anatomically separate from the GLP-1 signal, which is why the combination is being studied as additive in the phase 3 REDEFINE 1 programme [10].

The practical consequence for study design: receptor coverage scales with the number of mechanisms, but so does the surface area for adverse-effect exposure. Semaglutide offers the cleanest tolerability signal; retatrutide offers the largest reported weight-loss differential, but the least mature long-term safety record [1]. When choosing between these compounds it is worth weighing receptor breadth against study maturity, a balance that Retatrutide vs. semaglutide vs. tirzepatide breaks down compound by compound, with the associated titration arithmetic in How to dose retatrutide.

How to choose the right peptide for your weight-loss research

Match the peptide to the receptor pathway your protocol wants to study. The decision comes down to five mechanistic branches, each tied to a compound with its own receptor coverage and study maturity.

Single-pathway GLP-1 signal → semaglutide. Semaglutide isolates GLP-1 receptor activity without confounders from GIP, glucagon or amylin, and has the longest peer-reviewed safety record of the five [5].

Dual incretin synergy → tirzepatide. Tirzepatide is the right choice for studying GLP-1/GIP co-agonism, because GIP recruitment is thought to improve adipocyte lipid metabolism independently of GLP-1, which allows the additional contribution of the second incretin arm to be isolated.

Triple receptor coverage with a thermogenic signal → retatrutide. Retatrutide is the only triple agonist currently in late-stage development, and the glucagon arm is the mechanistic basis for the 24.2% mean weight loss at 48 weeks in the 2023 phase 2 obesity cohort [1]. In 2026 the phase 3 TRIUMPH-1 results were published (2,339 adults with obesity, 80 weeks): 25.0% mean weight loss with 12 mg against 3.9% with placebo [17].

Amylin and GLP-1 combination effects → CagriSema. CagriSema is the right choice when the research question concerns area postrema satiety pathways layered over the GLP-1 signal, with the phase 3 REDEFINE 1 results published in 2025 [10].

Visceral fat metabolism via the GH axis → tesamorelin. Tesamorelin suits studies of visceral fat and IGF-1-mediated lipolysis, although robust non-HIV VAT data from 2024 to 2026 remain scarce [9].

The choice of pen size depends on study duration and the target dose range: short pilot work (4–8 weeks) at low titration is handled by the pen with fewer total mg, while extended 24- to 48-week protocols following retatrutide's phase 2 schedule justify the pen with more total mg, which simply lasts longer. The dose dialled on the dose dial is the same on both sizes. For the full comparison of potency, half-life and titration arithmetic, see Retatrutide vs. semaglutide vs. tirzepatide; if you choose retatrutide, How to dose retatrutide describes the weekly 1 to 12 mg escalation schedule derived from the phase 2 protocol [1].

Body Pharm research pens: quality and traceability

Body Pharm research pens are pre-filled multi-dose devices with a 3 ml cartridge for subcutaneous injection, supplied with full batch traceability and sealed sterile packaging, solely for analytical and in vitro research, not for human consumption. The dose dial reads directly in milligrams, so the whole titration schedule is covered from the same cartridge: there is nothing to prepare before the first dose.

Batch traceability matters because reproducibility in peptide research depends on knowing the exact synthesis batch, the fill date and the dose tolerance behind every data point. A batch code printed on the pen and on the box allows observed receptor-binding or assay results to be attributed to a specific production batch, something indispensable when comparing titration cohorts across weeks 1 to 48 of a retatrutide-style protocol [1].

Key specifications of the current pen range:

• Format: pre-filled multi-dose pen with a 3 ml cartridge for subcutaneous injection; the dose dial reads directly in milligrams and there is no prior preparation
• Packaging: sealed sterile primary container with a tamper-evident outer box
• Traceability: batch code, fill date and total peptide amount on every unit
• Storage: between 2 and 8 °C protected from light; 24 months unopened; 12 months from the first puncture; up to 30 days at room temperature (30 °C maximum) without refrigeration; let it reach room temperature before injecting; do not freeze
• Shipping: to Spain, plain and discreet packaging, tracked shipping
• Intended use: solely for research and analytical purposes; not suitable for human consumption

If you are choosing between incretin agonists before ordering, the Retatrutide vs. semaglutide vs. tirzepatide breakdown covers receptor coverage and half-life, and How to dose retatrutide translates the weekly 1 to 12 mg escalation into the steps on the pen's dose dial.

Legal position: research peptides versus authorised medicines

Research peptides and authorised medicines for weight reduction belong to two separate regulatory categories. Authorised medicines such as Wegovy (semaglutide), Mounjaro (tirzepatide) and Saxenda (liraglutide) are prescription-only and are prescribed according to defined BMI and comorbidity criteria [6][11][12]. Research peptides, sold expressly for analytical and in vitro purposes, are not authorised medicines, are not prescribed and must not be administered to humans or animals.

Classification depends on the claims made and the intended purpose, not on the supplier's warnings: a peptide marketed to treat disease or to influence physiological functions is regarded as a medicinal product subject to authorisation, and supplying unauthorised products for human use is unlawful [3]. The authorities also continue to warn about counterfeit semaglutide circulating outside regulated distribution channels [15].

What this means for Body Pharm products

Body Pharm peptides are supplied solely for laboratory and analytical purposes and carry the express statement "Not for human consumption" on every unit. They are not authorised medicines, they are not substitutes for Wegovy or Mounjaro and they are not presented as such. If you order retatrutide, tirzepatide or tesamorelin, you are responsible for complying with the applicable pharmaceutical regulations, institutional research governance and all local rules on the handling and disposal of research compounds.

For comparative receptor data before buying, see Retatrutide vs. semaglutide vs. tirzepatide; for the in vitro titration mapping, see How to dose retatrutide.

Frequently Asked Questions: weight-loss peptides

What is the difference between retatrutide and tirzepatide?

Retatrutide activates the GLP-1, GIP and glucagon receptors, whereas tirzepatide is a dual GLP-1/GIP agonist with no glucagon activity [1][2]. Retatrutide's additional glucagon arm is linked to more pronounced hepatic lipolysis and to a greater reported weight reduction in the 2023 NEJM phase 2 data, where mean loss at 48 weeks reached 24.2% [1]. For a more detailed comparison, see Retatrutide vs. semaglutide vs. tirzepatide.

Is CagriSema available in Spain?

In 2026 CagriSema is not an authorised medicine, because, although the phase 3 REDEFINE 1 results from Novo Nordisk were published in 2025, no authorisation has been granted [10][14]. It is dealt with solely as a research compound for laboratory use, not as a prescription weight-reduction treatment. Body Pharm does not currently offer CagriSema in its catalogue.

What does "research peptide" mean?

A research peptide is a synthesised compound sold solely for in vitro and analytical laboratory work, because it holds no authorisation for human or animal use [3]. Classification depends on the claim and the intended purpose, so a research peptide must not be marketed, supplied or used to treat disease [3].

How are Body Pharm pens dosed?

Body Pharm pens are pre-filled multi-dose devices with a 3 ml cartridge. The number in the name is the total amount of peptide in the unit (for example, Retatrutide 32 mg or 64 mg, Tirzepatide 60 mg, Tesamorelin 32 mg) and the dose dial reads directly in milligrams, with no reconstitution and no volume calculation. Researchers typically map the in vitro escalation to the weekly phase 2 schedules of the published studies; the guide How to dose retatrutide describes the weekly 1 to 12 mg model from the 2023 phase 2 trial [1].

Are weight-loss peptides legal in Spain?

The authorised GLP-1 agonists (Wegovy, Mounjaro, Saxenda) can only be obtained legally on prescription [6][11][12]. Unauthorised peptides marketed for weight reduction in humans are unlawful; research peptides may only be supplied for laboratory and analytical purposes, and the authorities continue to act against illegal online offers and counterfeit semaglutide products [3][15].

What is the most potent weight-loss peptide available for research?

Retatrutide is currently the most potent weight-loss research peptide in the Body Pharm catalogue. Its triple GLP-1/GIP/glucagon agonism reached a 24.2% mean weight loss at 48 weeks in the 2023 phase 2 trial and so exceeded the published results for tirzepatide and semaglutide [1][2][5].

Next steps

If you want to select a peptide, start by reviewing the Retatrutide vs. semaglutide vs. tirzepatide comparison to match receptor coverage to your protocol's mechanistic endpoints. Once you have chosen the compound, consult the corresponding dosing guide, whether How to dose retatrutide, How to dose tirzepatide, How to dose CagriSema, How to dose semaglutide or How to dose tesamorelin, to settle the titration schedule and pen size. Then check the current 2026 prices and batch availability on the Body Pharm product page before ordering.

Sources

1. Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023. pubmed.ncbi.nlm.nih.gov/37366315
2. Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022. pubmed.ncbi.nlm.nih.gov/35658024
3. Directive 2001/83/EC, Article 1: definition of a medicinal product by presentation and by function; consolidated text on EUR-Lex. eur-lex.europa.eu — legal basis for a reagent labelled "research use only" remaining subject to pharmaceutical regulation if it is presented for human use.
4. Enebo LB, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial. Lancet. 2021. pubmed.ncbi.nlm.nih.gov/33894838
5. Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021. pubmed.ncbi.nlm.nih.gov/33567185
6. EMA, EPAR and Summary of Product Characteristics (SmPC) for Wegovy (semaglutide 2.4 mg): posology, escalation, missed doses and storage. ema.europa.eu
7. Lau DCW, et al. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. Lancet. 2021. pubmed.ncbi.nlm.nih.gov/34798060
8. ClinicalTrials.gov, retatrutide trial registry (phase 3 TRIUMPH programme), accessed October 2026. clinicaltrials.gov
9. Falutz J, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007. pubmed.ncbi.nlm.nih.gov/18057338
10. Garvey WT, et al. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity (REDEFINE 1). N Engl J Med. 2025;393:635-647. pubmed.ncbi.nlm.nih.gov/40544433
11. EMA, EPAR and Summary of Product Characteristics (SmPC) for Mounjaro (tirzepatide): EU authorisation and indications. ema.europa.eu
12. EMA, EPAR and Summary of Product Characteristics (SmPC) for Saxenda (liraglutide): EU authorisation and indications. ema.europa.eu
13. EMA, EPAR and Summary of Product Characteristics (SmPC) for Ozempic (semaglutide): EU authorisation for type 2 diabetes. ema.europa.eu
14. EMA, list of medicines for human use authorised in the EU (EPAR). ema.europa.eu — consulted in October 2026 for the regulatory status of retatrutide, CagriSema and tesamorelin.
15. EMA, "EMA alerts EU patients and healthcare professionals to reports of falsified Ozempic pens", news release of October 2023. ema.europa.eu
16. Finan B, et al. Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans. Sci Transl Med. 2013;5:209ra151. pubmed.ncbi.nlm.nih.gov/24174327
17. Jastreboff AM, et al. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity (TRIUMPH-1). N Engl J Med. 2026. pubmed.ncbi.nlm.nih.gov/42814954